Back to top

BioMarin Pharmaceutical (BMRN) Gets a Buy from Barclays

Barclays analyst Eliana Merle maintained a Buy rating on BioMarin Pharmaceutical today and set a price target of $105.00. According to TipRanks, Me...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioMarin Pharmaceutical Inc. (BMRN)